A planned safety analysis of a breast cancer prevention study using exemestane found an acceptable level of bone loss in postmenopausal women. The study also suggests that the long-term clinical impact of this decrease is not yet known, and further research is needed.
Mayo Clinic researchers found that young women with atypical hyperplasia had a relative risk of developing breast cancer almost six times greater than those without BBD. A strong family history of breast cancer slightly increased the risk in two other forms of benign breast disease, but only marginally.
The American Society for Cell Biology's Celldance contest reveals visually engaging and scientifically important cell-related content. This year's winners showcase stunning visuals of cellular processes, including Golgi ribbons and clathrin proteins, through videos and microscope stills.
A study by M.D. Anderson Cancer Center found that alternating mammography and MRI every six months can detect more breast cancers than traditional annual screening, with an accuracy of 71-100% compared to 16-40% for mammography alone. This approach detected nine cancers in high-risk women, including five identified only by MRI.
A University of Oregon expert argues that buildings are not just structures but places shaped by human interaction with the natural and built environment. The expert's approach to architecture, known as situated regionalism, prioritizes current needs and environmental responses over historical references.
Researchers found that Tau expression is predictive of survival, but in an unexpected way. Low Tau levels were linked to a good response to pre-operative chemotherapy and higher sensitivity to paclitaxel, but also a relatively poor overall survival rate.
Researchers at Mayo Clinic found a strong association between dense breasts and increased breast cancer risk, citing tissue composition differences between dense and non-dense tissue. Dense breast tissue contains more epithelium and stroma, and higher aromatase enzyme levels than non-dense tissue.
Postmenopausal women with a deficiency in the CYP2D6 gene have a nearly fourfold higher risk of early breast cancer recurrence when taking tamoxifen. Mayo Clinic researchers recommend testing for the gene before starting therapy.